Extraordinary Conceptions Announces US/UK Hybrid Surrogacy Programme

Extraordinary Conceptions, a global leader in surrogacy and egg donation with over two decades of experience, today announced the continued expansion of its U.S./UK Hybrid Surrogacy Programme, an international model that has successfully supported UK families for over five years.

Developed in response to long surrogate matching delays in the UK due to somewhat outdated surrogacy legislation, the Hybrid Programme enables intended parents to create embryos locally with their trusted UK fertility specialists, while moving their journey forward quickly through matching with thoroughly vetted U.S.-based surrogates. 

This approach provides families with access to enforceable legal contracts, pre-birth orders, and comprehensive medical and insurance protections available in the United States.

Through this established model, Extraordinary Conceptions has already supported numerous successful international surrogacy journeys, offering UK families a reliable, secure, and efficient alternative to domestic-only programs.

How the Hybrid Model Works

The program is structured around a seamless two-country journey, combining the best of both healthcare systems:

• IVF & Embryo Creation in the UK

Intended parents complete fertility treatment and embryo creation with their chosen UK specialists, maintaining continuity of care with physicians they know and trust.

• Surrogate Travel for Embryo Transfer

Once embryos are created, Extraordinary Conceptions matches families with a qualified U.S. surrogate—often within a significantly shorter timeframe than in the UK. The surrogate travels to the UK for the embryo transfer, which is managed under the guidance of the intended parents’ IVF clinic. Following the procedure, the surrogate returns to her home state to continue the pregnancy.

• U.S.-Managed Pregnancy & Delivery

The pregnancy, legal process, insurance coverage, and delivery are managed in the United States, including the establishment of parental rights through pre-birth orders and coordinated care at leading hospitals and fertility clinics.

• End-to-End Agency Support

Extraordinary Conceptions works closely with UK fertility clinics to coordinate every aspect of the journey—from matching and legal services to travel logistics, case management, and emotional support—ensuring a seamless experience.

“Our mission has always been to make surrogacy accessible, ethical, and transparent for families around the world. The Hybrid Program was built with UK families in mind — so they never have to choose between the doctors they trust and the legal security they deserve. Parents can have both," Hilary Smith, Head of International Development, Extraordinary Conceptions, told That's Health.

Transparent, Competitive Pricing

The Hybrid Surrogacy Programme is offered at an estimated total cost of USD $130,000 to $150,000, depending on individual medical circumstances. This comprehensive fee typically covers:

Full agency coordination, from initial consultation through surrogate matching

Surrogate compensation, wellness support, and living expense allowance

U.S.-based legal services, including surrogacy agreements and parental rights establishment

Surrogate medical insurance for the duration of the pregnancy

Round-trip travel and accommodation for the surrogate's UK embryo transfer

As demand for international fertility solutions continues to rise, the Hybrid Program represents a new benchmark for safe, ethical, and family-centered surrogacy care.

www.extraconceptions.com

Alzheimer's Diagnostic Blood Test Now Available in the UK

Advance Tests, a pioneer in advanced diagnostics, today announced the exclusive UK launch of LucentAD Complete, an innovative, multi-marker blood test that provides highly accurate risk classification for amyloid pathology associated with Alzheimer’s Disease.

Developed by Lucent Diagnostics, a commercial brand of Quanterix Corporation, this breakthrough diagnostic test combines several Alzheimer’s-related biomarkers, including p-Tau 217, to enhance early detection in patients with cognitive symptoms. 

This exclusive collaboration between Lucent Diagnostics and Advance Tests allows Advance Tests to deliver the test to patients and healthcare providers in the UK from December 2nd, marking a significant milestone in accessible Alzheimer’s diagnostics.

Key Advantages of LucentAD Complete:

Available Now: Bookings can be made now in the UK for appointments from December 2nd, introducing a biomarker blood test for clinical use for the very first time. Patient samples will be transported securely to the Lucent laboratories in the USA for analysis, with results made available within 15 working days.

High Accuracy: Achieves 90% accuracy in detecting amyloid pathology, in early-stage identification of Alzheimer’s.

Accessible: Priced at £695, LucentAD Complete is a cost-effective alternative to PET imaging and lumbar punctures, which can be significantly more expensive.

Non-Invasive: Requires only a blood sample, eliminating the need for invasive CSF collection and costly imaging procedures, in line with Advance Tests’ mission to make life-saving diagnostics widely accessible.

Reduced Uncertainty: The inclusion of multiple biomarkers in a sophisticated algorithmic model significantly reduces intermediate results, allowing nearly 90% of those being tested to receive a conclusive classification that either rules in or rules out Alzheimer’s Disease, far exceeding the standards set by the Global CEOi BBM Working Group.

The LucentAD Complete test utilizes p-Tau 217 along with additional biomarkers—Aβ42/40, GFAP, and NfL—to improve amyloid detection over single biomarker tests, delivering a result that either rules in or rules out amyloid pathology for approximately 90% of cases. The test meets the Global CEO Initiative on Alzheimer’s Disease’s (CEOi) and the US Alzheimer’s Association (AA) performance standards for plasma-based diagnostic tools, offering an advanced alternative to the current gold standard cerebrospinal fluid (CSF) or PET imaging approaches which are both highly invasive and considerably more expensive.

The test will be available on a private basis, with appointments for testing offered at Advance Tests’ first clinic located on St Thomas Street, beside Guy’s Hospital opposite London Bridge station. Additional clinics are planned for cities across the UK to expand patient access to this transformative diagnostic tool. Appointments can be booked now either directly or by healthcare providers via www.advancetests.com with appointments available from December 2nd 2024.

“We’re proud to exclusively bring LucentAD Complete to the UK, offering healthcare providers and patients a reliable and accessible diagnostic aid that can transform Alzheimer’s care,” said Dr. Simon Worrell, Founder and Chief Medical Officer of Advance Tests. “Our work with Quanterix strengthens our commitment to removing barriers to early diagnosis, enabling timely treatment that could profoundly impact patients’ lives.”

Dr. Karan Jutlla, Head of the Centre for Applied and Inclusive Health Research, University of Wolverhampton, commented on the introduction of LucentAD Complete: “Having access to this sophisticated, non-invasive blood test is a game-changer for early Alzheimer’s diagnosis in the UK. By simplifying diagnostics, we’re helping more patients access critical care sooner, especially as new therapies for early-stage Alzheimer’s are becoming available.”

For more information, visit www.advancetests.com.

Navigating the COVID Landscape: A British Perspective

As the world continues to grapple with the persistent challenge of COVID-19, the situation in Britain remains fluid, shaped by evolving variants, vaccination efforts, and public health measures.

In this blog post, we'll look into the current status of COVID-19 in Britain and explore effective strategies for dealing with an infection.

The Current Landscape:

At this juncture, Britain finds itself in a delicate balance between cautious optimism and ongoing vigilance. 

The rollout of vaccines has undoubtedly been a game-changer, providing a glimmer of hope amidst the uncertainty. However, the emergence of new variants, such as the Delta variant, serves as a stark reminder that the virus is far from defeated.

In recent months, we've witnessed fluctuations in case numbers, influenced by factors ranging from the relaxation of restrictions to seasonal trends. While some regions have experienced a decline in cases, others continue to grapple with outbreaks, underscoring the need for targeted interventions and community-wide cooperation.

Dealing with an Infection:

For individuals who find themselves facing a COVID-19 infection, navigating the experience can be daunting. Here are some key steps to consider:

Isolation: Upon receiving a positive test result or experiencing symptoms consistent with COVID-19, it's crucial to isolate yourself to prevent further transmission. This means staying home and avoiding contact with others, including household members, as much as possible.

Seeking Medical Advice: While many cases of COVID-19 are mild and can be managed at home, it's essential to seek medical advice, especially if you experience severe symptoms or belong to a high-risk group. Your healthcare provider can offer guidance tailored to your specific situation and recommend appropriate treatment options.

Monitoring Symptoms: Keep a close eye on your symptoms and seek medical attention if they worsen or if you develop new symptoms. Common signs of COVID-19 include fever, cough, shortness of breath, fatigue, and loss of taste or smell.

Rest and Hydration: Allow your body ample time to rest and recuperate. Stay hydrated by drinking plenty of fluids, and nourish your body with nutritious foods to support your immune system.

Follow Public Health Guidelines: Even while in isolation, continue to adhere to public health guidelines, such as wearing a mask, practicing good hand hygiene, and maintaining physical distance from others within your household.

Stay Connected: Despite the physical isolation, it's important to stay connected with loved ones through virtual means. Reach out for emotional support and stay informed about developments in your community.

Conclusion:

In the face of uncertainty, resilience and adaptability emerge as our greatest assets. By staying informed, following public health guidance, and supporting one another, we can navigate the challenges of COVID-19 with strength and solidarity. Together, we can weather this storm and emerge stronger on the other side. Stay safe, stay vigilant, and above all, stay hopeful.

Some useful resources:-

COVID Helpline 119

https://www.gov.uk/coronavirus

https://www.acas.org.uk/coronavirus

https://www.england.nhs.uk/coronavirus/post-covid-syndrome-long-covid

We would be grateful if you could share this blogpost and the information and resources with any vulnerable people you know.

Why International Thalassaemia Day on 8th May is Crucial

Every year, on the 8th of May, the global community comes together to commemorate International Thalassaemia Day. This observance holds immense significance, shedding light on a genetic blood disorder that affects millions worldwide. As a British citizen, it's important to understand the gravity of this day and why raising awareness about thalassaemia is crucial.

Thalassaemia is a hereditary blood disorder characterised by abnormal haemoglobin production, leading to anaemia and other complications. Individuals with thalassaemia require lifelong medical care, including frequent blood transfusions and chelation therapy to manage iron overload. Without proper treatment, thalassaemia can severely impact quality of life and lead to life-threatening complications.

In the United Kingdom, thalassaemia is a significant health concern, particularly among communities with a high prevalence of the gene mutation. South Asian, Mediterranean, Middle Eastern, and African communities are disproportionately affected by thalassaemia, highlighting the importance of culturally sensitive healthcare approaches and targeted awareness campaigns.

International Thalassaemia Day serves as a platform to raise awareness about the challenges faced by individuals living with thalassaemia and their families. It provides an opportunity to educate the public about the importance of carrier screening, genetic counselling, and early diagnosis to prevent the transmission of the disease to future generations.

Furthermore, this day serves as a reminder of the need for equitable access to healthcare services and treatment options for all individuals affected by thalassaemia, regardless of their socio-economic background or geographical location. In the UK, efforts to improve access to specialized thalassaemia care and support services are ongoing, but there is still much work to be done to ensure that every individual receives the care they need.

Moreover, International Thalassaemia Day is a call to action for policymakers, healthcare professionals, and communities to collaborate in addressing the challenges associated with thalassaemia. This includes supporting research initiatives aimed at developing more effective treatments, raising funds for patient support programmes, and advocating for policies that prioritize the needs of individuals living with thalassaemia.

As we observe International Thalassaemia Day on the 8th of May, let us reaffirm our commitment to supporting those affected by thalassaemia and working towards a future where this disorder no longer poses a threat to individuals and families. 

By raising awareness, promoting education, and advocating for better healthcare resources, we can make a meaningful difference in the lives of millions of people worldwide. Together, we can ensure that every individual living with thalassaemia receives the care, support, and respect they deserve.

The charity for the condition in the UK is UKTS https://ukts.org/

NHS workforce crisis needs immediate reforms alongside longer-term plans

With healthcare strikes in the news again, the Association of Professional Staffing Companies (APSCo) has warned that the NHS Workforce Plan is still missing the mark and will have little immediate impact on the skills crisis.

Tania Bowers, Global Public Policy Director at APSCo commented: “The workforce crisis in the NHS isn’t easily resolved and while the NHS Workforce Plan has been designed to create a more sustainable access to resources, the impact of most tactics could take 15+ years to be truly felt. APSCo has previously highlighted that access to globally trained healthcare professionals needs to be more widely available, but conversations with our members have highlighted a number of additional changes needed in this strategy.

“This includes a plan to ensure there are not only sufficient, but also appropriate, flexible training pathways that enable new routes into careers in healthcare. We also believe that there needs to be an assessment of how the funding and contractual terms for the supply of clinical staff are affecting the ability to change the supply pipeline and skill-mix.

“While attracting resources is a problem, retention issues also prevail and haven’t been covered in much detail in the plan. Workforce unrest and burnout are real problems in the healthcare sector and if these aren’t adequately addressed, the success of any recruitment strategies will be limited.

“Conversations with our members have also highlighted that there needs to be a more detailed assessment as to how the plan can be successfully delivered across all regions and what the implications of over or under supply will be.

“With strikes once again plaguing the sector, more immediate solutions are required beyond the Workforce Plan. In particular, the red tape many employers face when hiring agency workers needs to be cut. An example is the lack of conformity around pre-hiring compliance and safety checks of permanent and agency staff which is contributing to the increased costs and delays of getting nurses and doctors in front of patients. 

"A specialist, compliant to work for a Trust hospital under one CCG, may not necessarily be so at another hospital or primary care centre that operates under the same group, meaning there is minimal agility or responsiveness in workforce management.”

Find out more: www.apscouk.org